openPR Logo
Press release

Retinopathy of Prematurity Market is Expected to Witness Significant Growth from USD 13 Million in 2023, Driven by Advancements in Treatment Options | DelveInsight

04-25-2025 01:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Retinopathy of Prematurity treatment market report DelveInsight

Retinopathy of Prematurity treatment market report DelveInsight

The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness, improvements in neonatal care units, and increasing focus on preventive approaches.
DelveInsight's "Retinopathy of Prematurity Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of ROP, historical and forecasted epidemiology, as well as the therapeutic market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The retinopathy of prematurity market size in the 7MM was approximately USD 13 million in 2023, with the US accounting for approximately USD 8 million of this value. The ROP market is expected to grow steadily during the forecast period (2024-2034), driven by the introduction of novel therapies, advancements in neonatal care, increasing awareness of the importance of early eye examinations for premature infants, and the rising prevalence of premature births.

Download the Retinopathy of Prematurity Market report to understand which factors are driving the retinopathy of prematurity therapeutic market @ Retinopathy of Prematurity Market Trends [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

According to DelveInsight's analysis, the total number of incident cases of preterm infants by birth weight ( less than or equal to 1,500g) in the 7MM was approximately 94K in 2023, with these cases anticipated to increase during the study period of 2020-2034. Interestingly, there is a decreasing trend in preterm births ( less than or equal to 1,500g) in Germany, Italy, and Spain. Among the EU4 countries, Germany accounted for the highest number of incident cases of ROP, followed by France, whereas Spain had the lowest number of cases in 2023. Japan reported approximately 5K incident cases of ROP in 2023, with this number expected to rise during the forecast period.

Discover evolving trends in the retinopathy of prematurity patient pool forecasts @ Retinopathy of Prematurity Epidemiology Analysis [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report also explores the current and evolving retinopathy of prematurity treatment landscape. The current ROP treatment landscape primarily relies on laser therapy, which generated the highest revenue in the 7MM in 2023. Laser therapy has emerged as the standard of care aimed at countering the overproduction of vascular endothelial growth factor (VEGF) within the retina, a key factor contributing to the condition.

Anti-VEGF agents have become particularly valuable for infants for whom laser photocoagulation is difficult or impossible. Currently, there are only two retinopathy of prematurity approved drugs: EYLEA by Regeneron (NASDAQ: REGN)/Bayer (ETR: BAYN) and LUCENTIS by Novartis (SWX: NOVN). LUCENTIS is a humanized, high-affinity antibody fragment that binds to VEGF-A, while EYLEA is a VEGF inhibitor designed to block the growth of new blood vessels by targeting both VEGF-A and placental growth factor.

A notable treatment pattern observed is that only approximately 10% of the total ROP patients in the US and European countries, representing the severe and treatable pool, undergo any kind of treatment. In contrast, approximately 30% of ROP patients in Japan receive treatment, suggesting a more aggressive approach to management in this region. This difference highlights the variation in clinical practice across different healthcare systems, with Japanese ophthalmologists likely treating infants at an earlier stage of ROP compared to other countries.

The ROP pipeline is currently in the early stages of development, with most candidates focusing on preventive approaches rather than treatment. Key players such as FeliQS Corporation and Infant Bacterial Therapeutics (STO: IBT-B) are developing FLQ-101 and IBP-1118, respectively, both currently in preclinical stages for the retinopathy of prematurity prevention. In a significant development, the FDA granted Fast Track designation to FLQ-101 in November 2024, highlighting the recognition of unmet needs in this therapeutic area. FeliQS raised USD 2.5 million in 2022 to conduct pre-IND meetings with the FDA and manufacture the investigational drug, with a Phase 1b/2 study in both the US and Japan in the first quarter of 2025. In 2024, FLQ-101 also received Orphan Drug designation from the FDA.

Recent developments in the ROP market include the FDA's acceptance in February 2025 of Alvotech's biologics license application (BLA) for AVT06, a proposed biosimilar to EYLEA (Regeneron). Regulatory approval is expected to be completed in the fourth quarter of 2025, potentially expanding treatment options and improving accessibility.

Unlock which retinopathy of prematurity emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Retinopathy of Prematurity Drug Insights [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Looking ahead, the ROP market is expected to grow due to the development of better screening tools, the introduction of preventive treatments, and increased awareness about early detection. New treatment approaches for Retinopathy of Prematurity (ROP) aim to be faster and more efficient, allowing doctors to treat babies directly in local neonatal intensive care units (NICUs) without lengthy procedures or specialized anesthesia. These newer methods are expected to be more effective than traditional laser treatment, which, while helpful, can be stressful and time-consuming. Anti-VEGF drugs like EYLEA offer a quicker, FDA-approved alternative that can be given at the bedside without needing general anesthesia or costly laser equipment.

As research reveals more about the causes of ROP, new treatment options are likely to emerge, potentially changing how this serious eye condition is managed in vulnerable newborns.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Retinopathy of Prematurity

4. Key Events

5. Retinopathy of Prematurity Epidemiology and Market Forecast Methodology

6. Retinopathy of Prematurity Market Overview at a Glance

7. Disease Background and Overview

8. Epidemiology and Patient Population of the 7MM

9. Retinopathy of Prematurity Patient Journey

10. Retinopathy of Prematurity Marketed Drugs

11. Key Competitors for Pre-clinical Assets

12. Retinopathy of Prematurity: 7MM Analysis

13. Retinopathy of Prematurity Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

Related Reports:

Retinopathy Of Prematurity Pipeline Insight [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Retinopathy Of Prematurity Pipeline Insight provides comprehensive insights about the retinopathy of prematurity pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the retinopathy of prematurity companies, including Novartis, Regeneron, and Bayer, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinopathy-of-prematurity-market-is-expected-to-witness-significant-growth-from-usd-13-million-in-2023-driven-by-advancements-in-treatment-options-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retinopathy of Prematurity Market is Expected to Witness Significant Growth from USD 13 Million in 2023, Driven by Advancements in Treatment Options | DelveInsight here

News-ID: 3988375 • Views:

More Releases from ABNewswire

Tokyo Portfolio Launches Tokyo's #1 Real Estate Platform for Global Buyers
Tokyo Portfolio Launches Tokyo's #1 Real Estate Platform for Global Buyers
150K+ social subscribers, 12M+ views, and 200K+ monthly pageviews power Tokyo's leading English portal for highend homes Tokyo, Japan - August 29, 2025 - Tokyo Portfolio announced today that it has become Japan's mostwatched Englishlanguage brand focused on real estate, combining a large global audience with a highperforming listings portal for luxury rentals and purchases in Tokyo. The brand's videos and guides help expats and international buyers navigate one of the
Floor Boys Introduces Premium Pet-Friendly Flooring Solutions for South Carolina Homeowners
Floor Boys Introduces Premium Pet-Friendly Flooring Solutions for South Carolina …
Lexington-Based Flooring Specialist Offers Scratch-Resistant, Easy-Clean Flooring Options Perfect for Pet Owners LEXINGTON, SC - Floor Boys Flooring Professionals, backed by 125+ years of combined experience serving Lexington and surrounding South Carolina communities, announces its expanded focus on pet-friendly flooring solutions designed specifically for homeowners with dogs, cats, and other pets. The company specializes in scratch-resistant luxury vinyl plank (LVP), waterproof carpet, tile, and hardwood alternatives that combine durability with style
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more. It is now a lifestyle choice. Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better. In areas with seasonal weather, where people can be outside for most of the year, homeowners
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecedented Demand from Motor City Small Business Owners
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape. The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative

All 5 Releases


More Releases for Retinopathy

Global Diabetic Retinopathy (DR) Analysis Software Market Size by Application, T …
USA, New Jersey- According to Market Research Intellect, the global Diabetic Retinopathy (DR) Analysis Software market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The market for diabetic retinopathy (DR) analysis software is expanding steadily as a result of the rising incidence of diabetes and the
Diabetic Retinopathy Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Diffuse Large B-Cell Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 80+ Diffuse Large B Cell Lymphoma companies and 80+ Diffuse Large B Cell Lymphoma pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It
Diabetic Retinopathy Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Diabetic Retinopathy Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the
Diabetic Retinopathy Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Diabetic Retinopathy Pipeline constitutes 50+ key companies continuously working towards developing 55+ Diabetic Retinopathy Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Diabetic Retinopathy Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Diabetic Retinopathy NDA approvals
Diabetic Retinopathy - Drug Pipeline Landscape, 2022
New York, Global Diabetic Retinopathy Drug Pipeline Landscape report from Global Insight Services is the single authoritative source of intelligence on Diabetic Retinopathy Drug Pipeline Landscape. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market
Europe Diabetic Retinopathy Industry Analysis 2023
Overview Diabetic retinopathy (DR) is a watch ailment related to diabetic sufferers. The disorder takes place even as there may be dangerous to the retina due to diabetes. Without nicely-timed remedy, the disease also can reason bleeding inside the eyes, cloudy imaginative and prescient, and might even ruin the retina. DR is among the commonplace cause of loss of vision inside the diabetic population, sooner or later leading to blindness. From